HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.17
-0.14 (-1.05%)
At close: May 8, 2026, 4:00 PM EDT
13.13
-0.04 (-0.30%)
After-hours: May 8, 2026, 4:10 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
$305,408
Profits / Employee
$254,404
Market Cap
2.28B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Amneal Pharmaceuticals | 8,700 |
| Perrigo Company | 8,100 |
| Phibro Animal Health | 2,475 |
| ANI Pharmaceuticals | 970 |
| Supernus Pharmaceuticals | 778 |
| Prestige Consumer Healthcare | 600 |
| BioCryst Pharmaceuticals | 435 |
HCM News
- 10 days ago - HCM Receives Priority Review for New Drug Application in China - GuruFocus
- 11 days ago - Hutchmed says NDA for sovleplenib accepted in China - TheFly
- 11 days ago - HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference - Transcripts
- 12 days ago - HUTCHMED (China) Ltd (HCM) Shares Fall 3.9% -- GF Value Says Still Overvalued - GuruFocus
- 4 weeks ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewsWire
- 6 weeks ago - HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma - Nasdaq
- 6 weeks ago - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewsWire
- 7 weeks ago - HUTCHMED (China) Ltd (HCM) Shares Up 3.67% on Mar 16 - GuruFocus